Skip to content
Company Analysis

ClearPoint Neuro Inc. CLPT

A comprehensive view of key metrics, scores, and financial health for ClearPoint Neuro Inc.

Overview of ClearPoint Neuro, Inc.

CLPT NCM
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Small Cap
ClearPoint Neuro, Inc. (CLPT), is a Small Cap company, in the Medical Devices industry, last closed at $13.44, about 96.2% overvalued vs fair value, +16.5% 1Y return, ranked 734/1122 in sector.
USD 13.44
-2.89%
(Delayed)
• Vol 90d: 93.9%
52-Week Range
Market Cap
$412.40M
Enterprise Value
$409.92M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 87%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.clearpointneuro.co...
HQ Solana Beach, CA
Employees 115
Fiscal year Dec 31

Next Events

Earnings Aug 11 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$1
$1
Current: $13.44 -96% vs base

Engine Room Money Flow™

Small Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$31.4M
31%%
Gross Profit
$19.1M
40.5%%
Operating Income (GAAP)
$-19.7M
12%%
EBITDA
$-17.8M
15%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
60.9%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
0/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating ClearPoint Neuro Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
45
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
51
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing CLPT's balance between Growth (48.9%), Profitability (26.9%), and Safety (24.2%). Growth 49% Safety 24% Profitability 27%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

67th percentile vs peers
68
Key Signals
Rev Growth YoY 31.0% 85p Revenue CAGR 3Y 24.4% 79p EPS Growth YoY 22.1% 50p TSR -12.6% 41p Asset Growth YoY -8.1% 35p
Strengths
  • Rev Growth YoY in top 20% of peers (31.0%, 85th percentile)
  • Growth above peer median with strong metric coverage (85%)
Risks

No significant risks identified for this axis.

Profitability

37th percentile vs peers
37
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

33th percentile vs peers
34
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for ClearPoint Neuro Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$0.51
- - -
-96.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000